Protocols

UK sets up vaccines centre as Brexit looms; Shanghai’s Elpiscience bags $35M in Series B

Hillhouse Capital has joined Lilly Asia Ventures and CDH Investments in backing Elpiscience, leading a $35 million Series B to boost its cancer immunotherapy pipeline. The Shanghai-based biotech is gearing up IND filing for two of its 12 assets, several of which are in-licensed from regional and global institutions.

→ With Brexit threatening to disrupt the pharmaceutical supply chain in the country, and having lost the EMA headquarters to Amsterdam, the UK is working on ways to salvage its £70 billion life sciences industry. Over the weekend, the government announced the first-ever vaccines manufacturing innovation centre to tackle deadly diseases such as Ebola and Lassa fever.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->